Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- doxorubicin
- Elrexfio (elranatamab)
Interactions between your drugs
DOXOrubicin elranatamab
Applies to: doxorubicin, Elrexfio (elranatamab)
Using DOXOrubicin together with elranatamab or other chemotherapy drugs may increase the risk of side effects, especially those that affect the bone marrow or gastrointestinal tract. You may experience a greater number or more severe side effects such as nausea; vomiting; diarrhea; loss of appetite; mouth sores; abdominal pain; delayed wound healing; and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. You should seek medical attention if you develop paleness, fatigue, dizziness, fainting, unusual bruising or bleeding, fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. You may need a dose adjustment or more frequent monitoring by your doctor to safely use these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Carvykti
Carvykti (ciltacabtagene autoleucel) is used for the treatment of relapsed or refractory multiple ...
Abecma
Abecma is a CAR T cell therapy used to treat relapsed refractory multiple myeloma (RRMM); it is a ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Tecvayli
Tecvayli (teclistamab) is a treatment for relapsed or refractory multiple myeloma. Includes ...
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Talvey
Talvey is used to treat relapsed or refractory multiple myeloma. Includes Talvey side effects ...
Kisqali
Kisqali (ribociclib) is used to treat a certain type of advanced metastatic breast cancer. Includes ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.